



Fax completed form to: (855) 840-1678
 If this is an URGENT request, please call (800) 882-4462
 (800.88.CIGNA)

Oxlumo (lumasiran)

PHYSICIAN INFORMATION			PATIENT INFORMATION		
* Physician Name:			*Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.*		
Specialty:	* DEA, NPI or TIN:				
Office Contact Person:			* Patient Name:		
Office Phone:			* Cigna ID:	* Date of Birth:	
Office Fax:			* Patient Street Address:		
Office Street Address:			City:	State:	Zip:
City:	State:	Zip:	Patient Phone:		
Urgency: <input type="checkbox"/> Standard <input type="checkbox"/> Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)					
Medication Requested: <input type="checkbox"/> Oxlumo 94.5 mg/0.5ml vial ICD10: Directions for use: _____ Dose: _____ Quantity: _____ Duration of therapy: _____ What is the patient's body weight? _____					
Where will this medication be obtained? <input type="checkbox"/> Orsini Specialty Pharmacy <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> PANTHERx <input type="checkbox"/> Home Health / Home Infusion vendor <input type="checkbox"/> Retail pharmacy <input type="checkbox"/> Physician's office stock (billing on a medical claim form) <input type="checkbox"/> Other (please specify): _____					
Facility and/or doctor dispensing and administering medication: Facility Name: _____ State: _____ Tax ID#: _____ Address (City, State, Zip Code): _____					
Where will this drug be administered? <input type="checkbox"/> Patient's Home <input type="checkbox"/> Physician's Office <input type="checkbox"/> Hospital Outpatient <input type="checkbox"/> Other (please specify): _____ <p style="text-align: center;">NOTE: Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.</p> Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? <input type="checkbox"/> Yes <input type="checkbox"/> No (provide medical necessity rationale): _____					
Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? <input type="checkbox"/> Yes <input type="checkbox"/> No					
Clinical Information: **This drug requires supportive documentation (chart notes, genetic test results, etc.) be attached with this request** What is the diagnosis related to use: <input type="checkbox"/> Primary Hyperoxaluria Type 1 (PH1) <input type="checkbox"/> Primary Hyperoxaluria Type 2 (PH2) <input type="checkbox"/> Primary Hyperoxaluria Type 3 (PH3) <input type="checkbox"/> Post liver transplant <input type="checkbox"/> Other (please specify) _____					
Has the patient undergone genetic testing that confirmed biallelic pathogenic variants in the AGXT gene? <input type="checkbox"/> Yes <input type="checkbox"/> No (If no) Did the patient have a liver biopsy demonstrating absent, or significantly reduced alanine glyoxylate aminotransferase (AGT) activity? <input type="checkbox"/> Yes <input type="checkbox"/> No					

Prior to starting this drug, did/does the patient have a urinary oxalate level of at least 0.7 mmol/24 hours/1.73 meter²? Yes No

(if no) Prior to starting this drug, did/does the patient have an elevated urinary oxalate/creatinine ratio above the laboratory's age-specific normal reference range? Yes No

(if no) Prior to starting this drug, did/does the patient have a plasma oxalate level at least 20 micromoles (µmol)/L? Yes No

Is Oxlumo being prescribed by, or in consultation with, a nephrologist, urologist, or medical geneticist? Yes No

(if continuation of therapy) Has the patient had a documented reduction in urinary oxalate excretion? Yes No

(if continuation of therapy) Has the patient had a documented reduction in urinary oxalate/creatinine ratio? Yes No

(if continuation of therapy) Has the patient had a documented reduction in plasma oxalate levels from baseline? Yes No

(if continuation of therapy) Does the patient have documentation of improved, or stabilized clinical signs/symptoms of Primary Hyperoxaluria Type 1 (for example, nephrocalcinosis, formation of renal stones, renal impairment)? Yes No

Additional pertinent information (including prior therapy, disease stage, performance status, and names/doses/admin schedule of any agents to be used concurrently):

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature: _____ **Date:** _____

Save Time! Submit Online at: www.covermy meds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.

Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.

v031523

"Cigna" is a registered service mark, and the "Tree of Life" logo is a service mark, of Cigna Intellectual Property, Inc., licensed for use by Cigna Corporation and its operating subsidiaries. All products and services are provided by or through such operating subsidiaries and not by Cigna Corporation. Such operating subsidiaries include, for example, Cigna Health and Life Insurance Company and Cigna Health Management, Inc. Address: Cigna Pharmacy Services, PO Box 42005, Phoenix AZ 85080-2005